POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or
“POINT”), a company accelerating the discovery, development, and
global access to life-changing radiopharmaceuticals, and Athebio AG
(“Athebio”), an innovation leader in the discovery and design of
designed ankyrin repeat proteins (DARPins), today announced a
collaboration and license agreement to develop and commercialize
DARPin-targeted radioligands (“Radio-DARPins”).
DARPins are an attractive ligand class for
cell-surface targets that could enable access to cell “surfaceome”
targets beyond catalytic and ligand binding sites typically
accessible to small molecules and peptides. DARPins combine the
small molecule feature of rapid tumor penetration and clearance
from the body, with the antibody-like ability of binding to a wider
range of proteins and other cell surface targets. Their
well-behaved and customizable formatting options, including
stability at high concentrations and temperatures, are expected to
facilitate rapid discovery, validation, and commercial scale
manufacturing applicable to fast (212Pb) and slower (177Lu, 225Ac)
decaying isotopes.
The collaboration gives POINT exclusive access
to Athebio’s intellectual property and capabilities in DARPin
development in the radioligand therapy field. Together, the parties
will collaborate in discovery, candidate selection and preclinical
development of Athebody® DARPins for use as Radio-DARPin drug
entities. POINT will be solely responsible for the clinical
development and commercialization of Radio-DARPins translated from
the discovery collaboration.
“The holy grail of radioligand development is
the ability to engineer ligands that can precisely deliver
radiation and also have physical properties that are resistant to
radiolytic damage, enabling them to be manufactured at scale,” said
Joe McCann, Ph.D., Chief Executive Officer of POINT Biopharma.
“DARPins represent a potential goldilocks opportunity in this
regard, and could unlock new cell surface targets creating a new
horizon for the development of novel targeted radioligand
therapies. I am excited by this collaboration with Athebio, experts
in DARPin technology, as it further expands our library of tools to
engineer next-generation radioligands.”
“We are very excited to join forces with POINT.
POINT is uniquely positioned in the radiotherapy field and just as
committed as we are to unlock the full potential of Athebody®
DARPins to develop radiopharmaceuticals for patients in need,” said
Patrik Forrer, one of the inventors of the DARPin technology and
CEO and Chairman of Athebio. “The exceptional properties of our
Athebody® DARPins make them ideally suited for targeting
radioisotopes. In particular their high stability should allow for
simple conjugation to radioisotopes and their small size and high
affinity binding with precise specificity should allow for superior
targeting of tumors. The convergence of these attributes holds
immense promise for pushing the boundaries of radiotherapy.”
Terms were not disclosed.
About POINT
BiopharmaPOINT Biopharma Global Inc. is a globally focused
radiopharmaceutical company building a platform for the clinical
development and commercialization of radioligands that fight
cancer. POINT aims to transform precision oncology by combining a
portfolio of targeted radioligand assets, a seasoned management
team, an industry-leading pipeline, in-house manufacturing
capabilities, and secured supply for medical isotopes including
actinium-225 and lutetium-177. POINT’s active clinical trials
include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program
targeting fibroblast activation protein-α (FAP-α), and SPLASH, the
phase 3 trial for PNT2002 for people with metastatic castration
resistant prostate cancer (mCRPC) after second-line hormonal
treatment. Learn more about POINT Biopharma Global Inc.
at https://www.pointbiopharma.com/.
About ATHEBIO
AGATHEBIO enables its partners to develop superior
targeted therapeutics of advanced efficacy and safety and thereby
increased probability of clinical success. ATHEBIO’s proprietary
“plug & play” Athebody® platform is based on clinically
validated designed ankyrin repeat proteins (DARPins) and can unlock
therapeutic options not easily accessible with current antibody
technologies. Rather than building up its own pipeline, ATHEBIO
licenses tailor-made Athebody®️ DARPins to its partners. ATHEBIO
has brought the DARPin technology to the next level through the
development of its proprietary Athebody®️ DARPin platform. These
hyper-versatile binders can easily be plugged as building blocks
into a broad range of existing drug modalities. Athebody®️ DARPins
offer game-changing advantages for generating next-generation
multi-functional therapeutics – including excellent target
specificity and affinity, ease of generating multi-specificity,
high stability, small size, reliable folding, species
cross-reactivity, superb developability, and good
freedom-to-operate prospects.
Forward
Looking StatementsThis press release contains
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
In some cases, you can identify forward-looking statements by the
following words: “may,” “will,” “could,” “would,” “should,”
“expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “ongoing” or the
negative of these terms or other comparable terminology, although
not all forward-looking statements contain these words. These
statements involve risks, uncertainties and other factors that may
cause actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Although
we believe that we have a reasonable basis for each forward-looking
statement contained in this press release, we caution you that
these statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the benefits of the recently completed business combination, as
well as statements about the potential attributes and benefits of
POINT’s product candidates and the format and timing of POINT’s
product development activities and clinical trials. We cannot
assure you that the forward-looking statements in this press
release will prove to be accurate. These forward-looking statements
are subject to a number of significant risks and uncertainties that
could cause actual results to differ materially from expected
results, including, among others, our ability to grow and manage
our growth profitably and retain our key employees, the impact of
COVID-19 on our business, the success, cost and timing of our
product development activities and clinical trials, our ability to
obtain and maintain regulatory approval for our product candidates,
our ability to obtain funding for our operations, our the ability
to maintain the listing of our common stock on the NASDAQ, changes
in applicable laws or regulations, the possibility that POINT may
be adversely affected by other economic, business, and/or
competitive factors, and other risks and uncertainties, including
those described in our Annual Report on Form 10-K filed with the
SEC on March 27, 2023. Many of these factors are outside of POINT’s
control and are difficult to predict. Furthermore, if the
forward-looking statements prove to be inaccurate, the inaccuracy
may be material. In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by us or any other person that we
will achieve our objectives and plans in any specified time frame,
or at all. The forward-looking statements in this press release
represent our views as of the date of this press release. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we have no
current intention of doing so except to the extent required by
applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Investor
Relations Contact:Daniel PearlsteinDirector,
Strategyinvestors@pointbiopharma.com
ATHEBIO
Contact:Christian JostVP Early
Partneringcontact@athebio.com
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024